Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size.
He W., McCarroll CS., Nather K., Ford K., Mangion K., Riddell A., O'Toole D., Zaeri A., Corcoran D., Carrick D., Lee MMY., McEntegart M., Davie A., Good R., Lindsay MM., Eteiba H., Rocchiccioli P., Watkins S., Hood S., Shaukat A., McArthur L., Elliott EB., McClure J., Hawksby C., Martin T., Petrie MC., Oldroyd KG., Smith GL., Oxford Acute Myocardial Infarction (OxAMI) Study ., Channon KM., Berry C., Nicklin SA., Loughrey CM.
AIMS: Identifying novel mediators of lethal myocardial reperfusion injury that can be targeted during primary percutaneous coronary intervention (PPCI) is key to limiting the progression of patients with ST-elevation myocardial infarction (STEMI) to heart failure. Here, we show through parallel clinical and integrative preclinical studies the significance of the protease cathepsin-L on cardiac function during reperfusion injury. METHODS AND RESULTS: We found that direct cardiac release of cathepsin-L in STEMI patients (n = 76) immediately post-PPCI leads to elevated serum cathepsin-L levels and that serum levels of cathepsin-L in the first 24 h post-reperfusion are associated with reduced cardiac contractile function and increased infarct size. Preclinical studies demonstrate that inhibition of cathepsin-L release following reperfusion injury with CAA0225 reduces infarct size and improves cardiac contractile function by limiting abnormal cardiomyocyte calcium handling and apoptosis. CONCLUSION: Our findings suggest that cathepsin-L is a novel therapeutic target that could be exploited clinically to counteract the deleterious effects of acute reperfusion injury after an acute STEMI.